Reactive Robotics is developing robots for very early mobilization (VEM) using its patented, modular technology. Its device will be used for gait rehabilitation in neurological patients and in orthopedic patients after joint replacement. The company is aiming to design, manufacture and sell a rehabilitation robot that automates the gait rehabilitation process already extant in the ICU, but at a very early stage (i.e., 48 hours after the onset of neurological injury or joint replacement surgery).
The company’s objective is to set a new gold standard for VEM involving critically ill patients through a multi-pronged approach involving:
Reactive Robotics’ clients are hospitals that strive to provide patients with the best possible care during their path toward recovery and support their clinical staff with the best available technology.
As a long-term investor with a track record of creating successful and sustainable businesses, our goal is to deliver attractive strategic and financial returns to our investors.